21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

NCT ID: NCT03156361

Last Updated: 2018-07-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-18
• Study Completion Date: 2018-03-15

Brief Summary

Single Center, Double Blind, Active Comparator Controlled 2-Way Crossover Multiple Dose Safety, Tolerability and Efficacy Study

Detailed Description

This is a single center, double blind, active comparator controlled 2-Way crossover multiple dose safety, tolerability and efficacy study.

The study will consist of three periods. Total duration will be approximately nine weeks, including a screening period of up to 14 days, a 7-day run-in period and two 21-day treatment periods.

Subjects will be screened and then they will undergo a week of baseline CGM. They will then be randomized to one of two treatment sequences: three weeks of treatment with HDV-lispro followed by three weeks of treatment with insulin lispro diluted with sterile water to match the insulin concentration in HDV-lispro, or the same treatments in the reverse order.

A test meal study (standardized liquid test meal) is to be conducted at the beginning of treatment (baseline study) and at the end of each three week treatment period. As noted above, frequent blood samples will be collected for glucose and insulin levels during the first (baseline study) test meal; during the two test meals performed after the two treatment periods the same sampling for glucose and insulin will be performed, with the addition of collecting samples for glucagon levels.

Subjects will also perform blinded continuous glucose monitoring throughout the entirety of the study (7 weeks).

Throughout study, subjects will be asked to perform frequent self-monitoring of blood glucose (SMBG), at least 6 times per day (before and 60-90 minutes after each meal) during 3 or more days of each week. This will serve as data for therapeutic decision-making as well as for data collection.

Conditions

Type1 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

HDV insulin lispro 100 UNIT/mL

Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.

Group Type: EXPERIMENTAL

HDV insulin lispro 100 UNIT/mL

Intervention Type: DRUG

Hepatic Directed Vesicle (HDV) added to commercial insulin lispro

Insulin Lispro 100 UNIT/mL

Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro

Group Type: ACTIVE_COMPARATOR

Insulin Lispro 100 Units/mL

Intervention Type: DRUG

Sterile Water for Injection added to commercial insulin lispro

Interventions

HDV insulin lispro 100 UNIT/mL

Hepatic Directed Vesicle (HDV) added to commercial insulin lispro

Intervention Type: DRUG

Insulin Lispro 100 Units/mL

Sterile Water for Injection added to commercial insulin lispro

Intervention Type: DRUG

Other Intervention Names

HDV Humalog; Humalog

Eligibility Criteria

Inclusion Criteria

1. T1DM ≥12 months

2. C-peptide <0.6 ng/mL (a single re-test is allowable)

3. Treatment with rapid analog insulin by CSII for the previous 6 months

4. Familiarity with continuous glucose monitoring (CGM) technology; subjects nee d not be currently using CGM but should have used it in the past. Personal (unblinded) CGM will NOT be allowed during the study

5. Willingness to use insulin lispro as the analog insulin during the study period

6. Use of MiniMed Paradigm® pump for the previous 6 months. Pumps that employ low glucose suspend technology will NOT be allowed during the study

7. BMI ≥18.0 kg/m2 and ≤35.0 kg/m2

8. A1C≤9.0% (a single re-test is allowable)

Exclusion Criteria

1. Known or suspected allergy to any component of any of the study drugs in this trial.

2. A patient who has unstable proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.

3. Use of oral anti-diabetic or non-insulin anti-diabetic injection therapies (e.g. SGLT-2 inhibitors, pramlintide, GLP-1 agonists, etc.)

4. Current smokers; if a former smoker, no tobacco products (inhaled, oral or buccal) for the previous 3 months

5. As judged by the investigator, clinically significant active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on ECG), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure ≥ 100 mmHg and/or systolic blood pressure ≥ 160 mmHg after 5 minutes in the supine position).

6. History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the patient.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Integrium

INDUSTRY

Sponsor Role: collaborator

Diasome Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Douglas Muchmore, MD

Role: STUDY_DIRECTOR

Diasome Pharmaceuticals

Locations

Atlanta Diabetes Association

Atlanta, Georgia, United States

Countries

United States

Other Identifiers

DP 01-2017-02

Identifier Type: -

Identifier Source: org_study_id